vs

Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and Maxeon Solar Technologies, Ltd. (MAXN). Click either name above to swap in a different company.

Astrana Health, Inc. is the larger business by last-quarter revenue ($950.5M vs $509.0M, roughly 1.9× Maxeon Solar Technologies, Ltd.). Astrana Health, Inc. runs the higher net margin — 0.7% vs -120.7%, a 121.4% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs -54.7%). Astrana Health, Inc. produced more free cash flow last quarter ($-6.0M vs $-322.3M).

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

Maxeon Solar Technologies, Ltd. is a Singapore-based company that designs and manufactures photovoltaic panels. The company was previously a division of the American company SunPower. Maxeon was spun off from SunPower in August 2020. Maxeon was the primary provider of solar panels for SunPower through March 2024. Beyond the United States, Maxeon has sales operations in more than 100 countries and has the rights to use the SunPower brand in countries outside the United States.

ASTH vs MAXN — Head-to-Head

Bigger by revenue
ASTH
ASTH
1.9× larger
ASTH
$950.5M
$509.0M
MAXN
Growing faster (revenue YoY)
ASTH
ASTH
+97.6% gap
ASTH
42.9%
-54.7%
MAXN
Higher net margin
ASTH
ASTH
121.4% more per $
ASTH
0.7%
-120.7%
MAXN
More free cash flow
ASTH
ASTH
$316.4M more FCF
ASTH
$-6.0M
$-322.3M
MAXN

Income Statement — Q4 FY2025 vs Q4 FY2024

Metric
ASTH
ASTH
MAXN
MAXN
Revenue
$950.5M
$509.0M
Net Profit
$6.6M
$-614.3M
Gross Margin
Operating Margin
1.9%
-113.3%
Net Margin
0.7%
-120.7%
Revenue YoY
42.9%
-54.7%
Net Profit YoY
184.4%
-122.7%
EPS (diluted)
$0.12
$-96.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTH
ASTH
MAXN
MAXN
Q4 25
$950.5M
Q3 25
$956.0M
Q2 25
$654.8M
Q1 25
$620.4M
Q4 24
$665.2M
$509.0M
Q3 24
$478.7M
Q2 24
$486.3M
Q1 24
$404.4M
Net Profit
ASTH
ASTH
MAXN
MAXN
Q4 25
$6.6M
Q3 25
$373.0K
Q2 25
$9.4M
Q1 25
$6.7M
Q4 24
$-7.8M
$-614.3M
Q3 24
$16.1M
Q2 24
$19.2M
Q1 24
$14.8M
Operating Margin
ASTH
ASTH
MAXN
MAXN
Q4 25
1.9%
Q3 25
2.0%
Q2 25
3.1%
Q1 25
3.3%
Q4 24
0.1%
-113.3%
Q3 24
5.9%
Q2 24
6.2%
Q1 24
7.5%
Net Margin
ASTH
ASTH
MAXN
MAXN
Q4 25
0.7%
Q3 25
0.0%
Q2 25
1.4%
Q1 25
1.1%
Q4 24
-1.2%
-120.7%
Q3 24
3.4%
Q2 24
3.9%
Q1 24
3.7%
EPS (diluted)
ASTH
ASTH
MAXN
MAXN
Q4 25
$0.12
Q3 25
$0.01
Q2 25
$0.19
Q1 25
$0.14
Q4 24
$-0.14
$-96.00
Q3 24
$0.33
Q2 24
$0.40
Q1 24
$0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTH
ASTH
MAXN
MAXN
Cash + ST InvestmentsLiquidity on hand
$429.5M
$28.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$779.3M
$-293.8M
Total Assets
$2.2B
$376.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTH
ASTH
MAXN
MAXN
Q4 25
$429.5M
Q3 25
$463.4M
Q2 25
$342.1M
Q1 25
$260.9M
Q4 24
$290.8M
$28.9M
Q3 24
$350.3M
Q2 24
$327.7M
Q1 24
$337.3M
Stockholders' Equity
ASTH
ASTH
MAXN
MAXN
Q4 25
$779.3M
Q3 25
$775.5M
Q2 25
$765.5M
Q1 25
$745.4M
Q4 24
$712.7M
$-293.8M
Q3 24
$704.6M
Q2 24
$678.9M
Q1 24
$653.5M
Total Assets
ASTH
ASTH
MAXN
MAXN
Q4 25
$2.2B
Q3 25
$2.2B
Q2 25
$1.4B
Q1 25
$1.3B
Q4 24
$1.4B
$376.3M
Q3 24
$1.3B
Q2 24
$1.3B
Q1 24
$1.2B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTH
ASTH
MAXN
MAXN
Operating Cash FlowLast quarter
$-2.9M
$-270.2M
Free Cash FlowOCF − Capex
$-6.0M
$-322.3M
FCF MarginFCF / Revenue
-0.6%
-63.3%
Capex IntensityCapex / Revenue
0.3%
10.2%
Cash ConversionOCF / Net Profit
-0.44×
TTM Free Cash FlowTrailing 4 quarters
$104.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTH
ASTH
MAXN
MAXN
Q4 25
$-2.9M
Q3 25
$10.0M
Q2 25
$90.9M
Q1 25
$16.6M
Q4 24
$-10.9M
$-270.2M
Q3 24
$34.0M
Q2 24
$23.2M
Q1 24
$6.0M
Free Cash Flow
ASTH
ASTH
MAXN
MAXN
Q4 25
$-6.0M
Q3 25
$7.4M
Q2 25
$89.5M
Q1 25
$13.6M
Q4 24
$-13.5M
$-322.3M
Q3 24
$31.7M
Q2 24
$20.4M
Q1 24
$5.6M
FCF Margin
ASTH
ASTH
MAXN
MAXN
Q4 25
-0.6%
Q3 25
0.8%
Q2 25
13.7%
Q1 25
2.2%
Q4 24
-2.0%
-63.3%
Q3 24
6.6%
Q2 24
4.2%
Q1 24
1.4%
Capex Intensity
ASTH
ASTH
MAXN
MAXN
Q4 25
0.3%
Q3 25
0.3%
Q2 25
0.2%
Q1 25
0.5%
Q4 24
0.4%
10.2%
Q3 24
0.5%
Q2 24
0.6%
Q1 24
0.1%
Cash Conversion
ASTH
ASTH
MAXN
MAXN
Q4 25
-0.44×
Q3 25
26.69×
Q2 25
9.65×
Q1 25
2.48×
Q4 24
Q3 24
2.11×
Q2 24
1.21×
Q1 24
0.40×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

MAXN
MAXN

Segment breakdown not available.

Related Comparisons